Compare Kohl's Corporation (KSS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Sanofi SA — how do they compare? Kohl's Corporation trades at $20.35 (market cap $2.28B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 41.7× Kohl's Corporation's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Sanofi SA for 94 Days on average.
| KSS | SNY | |
|---|---|---|
Market Cap | $2.28B | $95.18B |
Volume | 4,960,280 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $52.34 |
52-Week Low | $11.72 | $39.51 |
Typical Hold Time | 48 Days | 94 Days |
Enterprise Value | $7.88B | $114.48B |
Dividend Yield | 2.49% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $20.10, down 0.1% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and a new merchandising appointment signal operational improvements. Revenue trends show stabilization after several quarters of decline, with 2026 projections indicating potential margin recovery.
KSS presents a value opportunity with deep discount to sector peers, though persistent sales declines and competitive pressures remain headwinds. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism amid turnaround execution risks.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
